Business
-
Inhaled mRNA developer Ethris has signed an agreement with the European Investment Bank (EIB), and the European Commission’s Health Emergency Preparedness and Response Authority (DG HERA) for a €30 million financing to support clinical development… Read more . . .
-
Glenmark Pharmaceuticals has announced that Ryaltris olopatadine / mometasone nasal spray was approved by ANVISA earlier this year for the treatment of allergic rhinitis in patients aged 12 and over and that the company has… Read more . . .
-
Leyden Laboratories has announced that it acquired intranasal RNA therapy developer RIGImmune sometime earlier this year. The company also reported results from a Phase 1 study of RIGImmune’s RIG-101, an intranasal innate immune modulator for… Read more . . .
-
MannKind and Rose Pharma have announced a collaboration agreement that gives Rose a worldwide license for development of its ROSE-010 rapid-acting GLP-1 as an inhaled therapy for weight loss using MannKind’s Technosphere dry powder technology.… Read more . . .
-
Aurobindo Pharma announced that its newly-acquired US subsidiary Lannett has launched 100/50 mcg and 250/50 mcg strengths of a generic version of Advair Diskus fluticasone propionate / salmeterol xinafoate DPI in the US. Aurobindo notes that… Read more . . .
-
According to ENA Respiratory, the company has received AU$2.98 million in funding from the new Australian “national virtual incubator” Biointelect Venturer, with the funds going to support a Phase 1b study of ENA’s INNA-051 dry powder… Read more . . .
-
Scienture Holdings announced that the company has launched Rezenopy naloxone nasal spray in the US. Scienture acquired the US rights to Rezenopy from Summit Biosciences, a subsidiary of Kindeva Drug Delivery, in 2025. The FDA approved Summit’s… Read more . . .
-
Zydus Lifesciences has announced the launch of its Revahale revefenacin inhalation solution in India. The company highlights that Revahale is the country’s first once-daily nubulized LAMA for the treatment of COPD, noting that the inhalation… Read more . . .
-
ReCode Therapeutics, which is developing inhaled mRNA therapies, announced that Heather Clark will succeed Shehnaaz Suliman as the company’s CEO, with Suliman becoming executive chair of the board. Clark joined ReCode in 2022 and has… Read more . . .
-
US-based opthalmic pharmaceuticals company Harrow announced that it will pay Viatris $30 million up front and up to $70 million in milestone payments to acquire Tyrvaya varenicline nasal spray. Tyrvaya was approved by the FDA… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland